Therapeutic plasma exchange addresses the root causes of complex conditions by removing harmful proteins, antibodies, and inflammatory factors from the blood.
The AMBAR (Alzheimer's Management By Albumin Replacement) trial is a landmark multicenter, randomized, double-blind, placebo-controlled study. This study enrolled 322 patients with mild-to-moderate Alzheimer's disease across sites in the United States and Europe.
The results were striking: patients receiving therapeutic plasma exchange with albumin replacement showed 52–71% slowing of cognitive and functional decline compared to placebo. The treatment was well-tolerated with a safety profile consistent with over 50 years of TPE clinical use.
The AMBAR trial suggests that removing aging and inflammatory plasma proteins — including amyloid-beta, tau fragments, and pro-inflammatory cytokines — and replacing them with purified albumin provides meaningful clinical benefit for Alzheimer's patients, particularly in the early-to-moderate stages of disease.
Cognitive and functional decline was slowed by 52–71% in the treatment group compared to placebo across validated assessment scales.
Multicenter, randomized, double-blind, placebo-controlled trial across sites in the United States and Europe.
Unlike monoclonal antibody treatments, TPE carries no risk of ARIA (brain swelling and microbleeds) — serious adverse events that have limited the adoption of newer Alzheimer’s drugs.
FDA-approved monoclonal antibody treatments such as lecanemab and donanemab represent meaningful progress in Alzheimer's care. Like any treatment, they carry risks — most notably amyloid-related imaging abnormalities (ARIA), which include brain swelling and microbleeds in a subset of patients.
Therapeutic plasma exchange offers a fundamentally different approach. Rather than targeting a single protein, TPE removes the full spectrum of aging and inflammatory factors from the blood — including amyloid-beta, tau, and pro-inflammatory cytokines — while replacing them with purified albumin.
The AMBAR trial demonstrated comparable or superior efficacy in slowing decline, with a safety profile backed by over 50 years of clinical use and zero risk of ARIA.
As we age, our plasma accumulates pro-inflammatory proteins, damaged albumin, and aging-associated factors that signal deterioration to every cell in the body. These circulating molecules are increasingly recognized as primary drivers of biological aging.
Therapeutic plasma exchange removes this burden in a single session, replacing old plasma with purified albumin — one of the body’s most potent natural anti-inflammatory and antioxidant proteins. The result is a measurable reset of the circulating environment, creating conditions that support cellular repair and regeneration.
Dr. Kiprov’s research, first published in GeroScience in 2022, demonstrated that TPE measurably reduces biological age. A subsequent multi-omics study conducted with the Buck Institute for Research on Aging validated and expanded these findings across 35 epigenetic clocks.
Kim et al. (2022), published in GeroScience, demonstrated that TPE reduces biological age by 1–3 years as measured by validated Horvath and GrimAge epigenetic clocks.
The Buck Institute for Research on Aging independently confirmed these findings across 35 distinct epigenetic clocks, published in Aging Cell.
Therapeutic plasma exchange has a well-documented safety profile spanning more than 50 years of worldwide clinical use.
In autoimmune disorders, the immune system produces antibodies that mistakenly attack the body's own tissues — nerves, muscles, the blood-brain barrier, and other vital structures. These pathogenic antibodies circulate in the plasma, continuously driving inflammation and tissue damage.
Therapeutic plasma exchange directly removes these antibodies, immune complexes, and inflammatory cytokines from the blood. Unlike immunosuppressive medications — which may take weeks or months to reduce antibody levels — TPE provides immediate reduction, offering meaningful symptomatic relief in acute crises and improved disease control in chronic conditions.
TPE is recognized as a first-line or second-line treatment for numerous autoimmune conditions by the American Society for Apheresis (ASFA), and Dr. Kiprov — a founding member of ASFA — has over 40 years of experience treating these conditions with therapeutic apheresis.
TPE rapidly removes acetylcholine receptor antibodies that cause progressive muscle weakness, providing relief when conventional immunosuppression is inadequate or too slow to act.
Therapeutic plasma exchange is a first-line treatment for GBS, removing the anti-ganglioside antibodies that attack peripheral nerves and cause ascending paralysis.
TPE removes the pathogenic antibodies driving chronic nerve demyelination, offering an alternative or adjunct to IVIG therapy for patients with CIDP.
For severe MS relapses that are refractory to high-dose corticosteroids, TPE can remove the inflammatory mediators and antibodies driving acute demyelination.
TPE targets aquaporin-4 antibodies, the primary driver of NMO, reducing the risk of devastating optic neuritis and transverse myelitis attacks.
Removal of pathogenic antibodies — including anti-NMDA receptor antibodies — that attack brain tissue, causing seizures, psychiatric symptoms, and cognitive decline.
Infections can trigger persistent immune dysregulation that continues long after the original pathogen has been cleared. In conditions like PANS/PANDAS and Long COVID, the immune system produces autoantibodies and inflammatory mediators that circulate in the plasma, attacking the body's own tissues and driving debilitating symptoms.
Conventional treatments — antibiotics, anti-inflammatories, immunosuppressants — address part of the problem but cannot physically remove the pathogenic autoantibodies and inflammatory factors already circulating in the blood. Therapeutic plasma exchange can.
By removing and replacing the plasma, TPE eliminates the circulating autoantibodies, pro-inflammatory cytokines, microclot-promoting factors, and other pathogenic molecules that perpetuate post-infectious syndromes — often providing relief when other interventions have failed.
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and PANDAS are triggered by infections — most commonly streptococcal — that produce autoantibodies attacking the basal ganglia. TPE removes these pathogenic antibodies, offering meaningful symptom improvement for neuropsychiatric symptoms including OCD, tics, anxiety, cognitive regression, and behavioral changes.
Long COVID is characterized by persistent symptoms — fatigue, brain fog, autonomic dysfunction, and exercise intolerance — lasting weeks to months after acute infection. Growing evidence links these symptoms to persistent inflammatory factors, autoantibodies, and microclots circulating in the plasma. TPE removes these pathogenic factors that conventional treatments cannot address.
Many patients develop chronic fatigue and immune dysregulation following viral infections beyond COVID-19 — including EBV, influenza, and other pathogens. TPE addresses the circulating inflammatory mediators and autoantibodies that perpetuate symptoms long after the infection has cleared.
Schedule a free discovery call with our physicians to discuss whether therapeutic plasma exchange is right for you.
Book a Free Discovery Call